Journal
ONCOTARGET
Volume 2, Issue 3, Pages 135-164Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.240
Keywords
Targeted Therapy; Combination Therapy; Drug Resistance; Cancer Stem Cells; Aging; Senescence; Raf; Akt; PI3K; mTOR
Categories
Funding
- Fondazione del Monte di Bologna e Ravenna [IGF-1, RBAP10447J]
Ask authors/readers for more resources
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Integral components of these pathways, Ras, B-Raf, PI3K, and PTEN are also activated/inactivated by mutations. These pathways have profound effects on proliferative, apoptotic and differentiation pathways. Dysregulation of these pathways can contribute to chemotherapeutic drug resistance, proliferation of cancer initiating cells (CICs) and premature aging. This review will evaluate more recently described potential uses of MEK, PI3K, Akt and mTOR inhibitors in the proliferation of malignant cells, suppression of CICs, cellular senescence and prevention of aging. Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways play key roles in the regulation of normal and malignant cell growth. Inhibitors targeting these pathways have many potential uses from suppression of cancer, proliferative diseases as well as aging.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available